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Phenotypic Heterogeneity of Primitive Leukemic Hematopoietic Cells in Patients
With Chronic Myeloid Leukemia By C. Udomsakdi, C.J. Eaves, P.M. Lansdorp, and A.C. Eaves
The peripheral blood of chronic myeloid leukemia (CML) patients with chronic-phase disease and elevated white blood cell (WBC) counts typically contains markedly increased numbers of a variety of neoplastic pluripotent and lineage-restricted hematopoietic progenitors. These include cells detected in standard colony assays as well as their more primitive precursors. The latter are referred t o as long-term culture-initiating cells (LTC-IC) because of their ability t o generate clonogenic cell progeny detectable after a minimum of 5 weeks incubation on competent fibroblast feeder layers.
In this study, we have investigated a number of the properties of the LTC-IC and clonogenic cells present in the blood of such CML patients with high WBC counts. This included an analysis of the light scattering properties of these progenitors, as well as their expression of CD34 and HLA-DR, Rhodamine-123 staining, and in vitro sensitivity t o 4-hydroperoxycyclophosphamide. In the case of LTC-IC, the production of different types of lineage-restricted and multipotent progeny was also analyzed. Most of the circulating LTC-IC and clonogenic cells in the CML patients studied (on average -70% and -go%, respectively) showed features of proliferat-HILADELPHIA chromosome (Phl)-positive chronic P myeloid leukemia (CML) is a well-defined, two-stage, clonal myeloproliferative disease. The initial, chronic phase is characterized by a pronounced but benign leukocytosis. The second, acute phase is characterized by the appearance of a rapidly expanding subpopulation of blasts that fail to differentiate, are unresponsive to chemotherapy, and lead rapidly to death. Ready demonstration of the Ph' chromosome in multiple hematopoietic cell types, including B cells as well as myeloid cells, suggests that the neoplastic clone originates in a pluripotent stem cell.' At a molecular level, CML is associated with the creation of a fusion gene between most of c-ABL (from chromosome 9) and some of BCR-1 (on chromosome 22).2 Transcription of this fusion gene leads to the synthesis of a protein with several altered properties relative to ~1 4 5~-"~' , including increased tyrosine kinase a~tivity.3.~ Recently, a CML-like disease has been observed to arise in mice whose hematopoietic cells have been genetically 0006-4971 1921 801 0-001 0$3.00/ 0 ing or activated cells. This is in marked contrast t o the majority of progenitors in the blood of normal individuals and most of the LTC-IC in normal marrow, all of which exhibit a phenotype expected of quiescent cells. Interestingly, a significant proportion of the circulating clonogenic cells and LTC-IC in the CML samples studied (on average -10% and -30%. respectively) appeared t o be phenotypically similar t o normal circulating progenitors, although their absolute numbers were indicative of a neoplastic origin. Both phenotypes of circulating CML clonogenic cells and LTC-IC could be obtained at approximately 10% t o 20% purity by differential multiparameter sorting. These findings suggest that expansion of the Philadelphia chromosome-positive clone at the level of the earliest types of hematopoietic cells results from the activation of mechanisms that enable some, but not all, signals that block the cycling of normal stem cells t o be bypassed or overcome. In addition, they provide strategies for purifying these primitive leukemic cells that should facilitate further analysis of the mechanisms underlying their abnormal proliferative behavior.
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engineered to express various BCR-ABL constructs.5-7 Such findings provide further evidence that this gene product plays a primary role in the pathogenesis of CML in humans. A number of functions have been recently assigned to specific regions of the normal products of BCR-1 and c-ABL and several essential for (or able to contribute to) the transforming potential of BCR-ABL fusion genes have been identified. [8] [9] [10] [11] [12] [13] [14] [15] In contrast, very little is known about the control of BCR-ABL expression in different primary hematopoietic cell types, particularly progenitor cells, or the biologic consequences of such expression. The most primitive hematopoietic cells are difficult to study because they make up such a small proportion of all the nucleated cells in the blood and marrow. Nevertheless, effects of BCR-ABL expression on their behavior are of key interest because it is these cells that are believed to be responsible for the initial amplification and subsequent maintenance of the leukemic clone in patients with CML.
Such studies require not only specific, quantitative assays for the relevant cells, but also methods for their characterization and ultimately for their isolation as pure populations. The assay for long-term culture-initiating cells (LTC-IC) appears to qualify as one that detects a population more primitive than clonogenic celW and that may overlap with totipotent reconstituting cell^.^^-'^ This assay also detects a functionally analogous cell present at low frequency in CML marrow and in markedly elevated concentrations in the blood of CML patients with high white blood cell (WBC) counts.20 A characteristic feature of a variety of primitive Phl-positive clonogenic cell types is that their proliferation is deregulated both in vivo21 and in vitrozz under conditions in which their normal counterparts are quiescent, suggesting perturbation of a control mechanism also active on the most primitive normal hematopoietic cells. It might therefore be expected that Phl-positive LTC-IC would also exhibit properties of cycling cells, in PHENOTYPE OF CML STEM CELLS 2523 contrast to normal LTC-IC. The present studies were designed to test this prediction. To facilitate the characterization of Phl-positive clonogenic cells and LTC-IC, peripheral blood (PB) from CML patients with elevated WBC counts was used as starting material. This made laborious genotyping studies (by polymerase chain reaction [PCR] or cytogenetic analysis of their individual progeny) unnecessary, because of the very marked increase in all types of circulating neoplastic progenitors in such patients, thereby increasing both the number of experiments that could be performed and the precision of the measurements made.
MATERIALS AND METHODS

Cells.
Heparinized blood samples were obtained with informed consent from CML patients undergoing routine hematologic assessment. All patients were Phl-positive and in chronic phase. As shown in Table 1 , the number of circulating LTC-IC in all patients studied was abnormally elevated (by a factor of from > 400-fold to -105-fold above the average normal value of -2.9 f 0.5/mL).2°,23
The light-density fraction ( < 1.077 g/mL) was isolated by centrifugation of the blood on ficoll-hypaque (FH) to eliminate the majority of erythrocytes, granulocytes, and platelets and to obtain a preliminary enrichment of progenitor cells. Normal blood samples were obtained with informed consent from normal individuals undergoing platelet/leukapheresis and from these a light-density T-cell-depleted fraction was then isolated by rosetting with sheep erythrocytes and centrifugation on FH as previously d e s~r i b e d ?~-~~ The number of remaining CD2+ (T cells) detected by FACScan analysis of this T-cell-depleted, light-density fraction of normal blood cells represented, on average, less than 2% of the total. Because the number of T cells in initial CML blood samples was already at or below this level, the T-cell-depletion step was not performed on CML blood samples. Heparinized normal marrow aspirate cells were leftovers obtained with informed consent from allogeneic donors providing marrow for transplantation.
Cells were washed twice and resuspended in Hank's solution with 2% fetal calf serum (FCS) and 0.1% sodium azide (NaN3) (HFN). Cells were first stained with an anti-CD34 antibody (8G12) directly conjugated to phycoerythrin (PE) or fluorescein isothiocyanate (FITC) as described previouslyzs and then double-stained with 0.1 pg/mL Rhodamine-123 (Rh-123)26 or 1 to 2 pg of anti-HLA-DR-PE (lo7 cells/mL). 16 Stained cells were analyzed and sorted using a Becton Dickinson FACStarPIUS fluorescence-activated cell sorter (FACS) equipped with an argon laser emitting at 488 nm. Fluorescence of Rh-123-, Staining and flow cytomefry. FITC-, and PE-labeled cells was measured using 530/30 and 575/26 band pass filters, respectively, after calibration of the FACS before each sort with 10 pm fluorescent beads. In some experiments, gates were set to exclude most of the granulocytes and erythrocytes using previously described forward light scatter (FSC) and side scatter (SSC) characteristicsJ6 Cells appearing within this light scatter window ( Fig 1A) constituted on average 15% to 20% of the total light density fraction of CML blood cells. Sorted cells were collected in Hank's solution with 50% FCS and were maintained at 4°C until plated.
Cells from primary blood samples or from LTC harvests were assayed for clonogenic erythropoietic (burstforming units-erythroid [BFU-E]), granulopoietic (colony-forming units granulocyte-macrophage [CFU-GM]), and multilineage (CFUgranulocyte, erythroid, monocyte, megakaryocyte [CFU-GEMM]) progenitors in standard methylcellulose cultures containing 3 U/mL of human erythropoietin and 10% agar-stimulated human peripheral leukocyte-conditioned medium (Terry Fox Laboratory Media Preparation Service, Vancouver, British Columbia, Canada). The methodology for colony generation and criteria for colony recognition were the same as have been used for many years in this l a b o r a t~r y .~~ Total clonogenic cell numbers refers to the sum of BFU-E, CFU-GM, and CFU-GEMM detected in direct assays using these procedures. LTC-IC assays were performed by seeding an aliquot of the test cell suspension into cultures containing a feeder layer of irradiated (1,500 cGy) normal (allogeneic) marrow cells (3 x IO4 cells/cm2). These were subcultured from the adherent layer of previously established 2-to 4-week-old LTCJ2sZ8 LTC were initially maintained for 3 to 5 days at 37°C and then switched to 33°C thereafter. They were then fed weekly by replacement of half of the growth medium (an enriched a-medium containing 12.5% horse serum, 12.5% FCS, mol/L 2-mercaptoethanol, and mol/L hydrocortisone) containing half of the nonadherent cells with fresh growth medium. After a total of 5 weeks, or as specified, the nonadherent cells were removed, washed, and combined with cells from those harvested from the trypsinized adherent layer.27.29 These harvested LTC cells were then assayed for clonogenic cells in standard methylcellulose cultures at an appropriate concentration (usually 5 x IO4 or 105 cells per 1.1 mL assay). The total number of clonogenic cells (ie, BFU-E plus CFU-GM plus CFU-GEMM) present in 5-week-old LTC provides a relative measure of the number of LTC-IC originally present in the test suspension.20.z In some cases, absolute LTC-IC values were calculated by dividing this number by 3, which is the average output of clonogenic cells per leukemic LTC-IC, as shown previously by limiting dilution analysis."
RESULTS
Phenotype analysis of CML LTC-IC.
To determine the light scattering properties of circulating clonogenic cells and LTC-IC in patients with CML, light-density blood cells were sorted into three fractions (as illustrated in Fig 1A) and the results compared with data for normal bone marrow (BM)16 and blood23 progenitors (Fig 1B) . Most of the nucleated cells ( -85%) in the light-density fraction of CML blood had a high SSC (fraction 111) in contrast to the light-density cells in normal blood, where the proportion of such cells is much lower (<40%, data not shown). The mean number of clonogenic cells and LTC-IC recovered in each sorted fraction was determined and expressed as a percentage of the total number of progenitors present in the starting (light-density) cell suspension of each sample studied. As shown in Fig lB, clonogenic cells and LTC-IC in CML blood were consistently found in fraction I1 (ie, cells with high FSC but low SSC). Cells from this fraction also generally produced more nucleated cells (as well as clonogenic cells) after 5 weeks in LTC (both in the adherent and nonadherent layer) than other fractions on a per cell basis (data not shown). However, a significant proportion of the circulating CML clonogenic cells ( -15%) and LTC-IC ( -30%) were detected in a population characterized by low FSC and low SSC (fraction I). Some circulating CML clonogenic cells (-5%) were found among the cells with a high SSC (fraction 111). These findings suggest subtle differences between circulating CML clonogenic cells and LTC-IC in terms of their overall light scattering properties. This was reinforced by experiments in which fraction I1 was subdivided further into 2 to 3 fractions. Analysis of these showed that the circulating CML clonogenic cells were more concentrated in fractions containing cells with a slightly higher FSC by comparison to the distribution of LTC-IC in the same fractions (data not shown). The high FSC of circulating clonogenic cells in CML patients differs markedly from the FSC typical of clonogenic cells in the circulation of normal individual^,^^ but is very similar to the majority of clonogenic cells in normal BM. 16 Because very few progenitors were present in fraction 111, only cells in fractions I and I1 were analyzed in all subsequent sorts. Figure 2 shows representative distributions of lightdensity normal and CML blood cells gated for low SSC after two-color staining for expression of CD34 and HLA-DR, or expression of CD34 and uptake of Rh-123. A much larger proportion of light-density CML blood cells were found to express readily detectable levels of CD34 than is the case for normal blood cells in the same light scatter window (compare Fig 2D and F with C and E) . The CML cells also contained a higher proportion of cells that expressed readily detectable levels of HLA-DR or that retained Rh-123 by comparison to normal blood.23 Figures   3 and 4 show the results obtained when the CD34+SSC10W cells were sorted according to their expression of HLA-DR (Fig 3) or Rh-123 uptake (Fig 4) and were then analyzed functionally for clonogenic cell and LTC-IC content. It can be seen that most of the clonogenic cells in CML blood, like most of the clonogenic cells in normal marrow, expressed readily detectable levels of HLA-DR (Fig 3A) and showed positive staining with Rh-123 (Fig 4A) .l6xZ6 In this respect, however, they both differ markedly from the clonogenic cells found in normal blood, of which very few show a DRhrgh or Rh-123hrrght phenotype.23 Further subdivision of the CD34+DRh1gh fraction of CML blood cells into DR+ and DR++ subpopulations (as defined in Fig 2D) showed the presence of clonogenic cells in both (Tables 2 and 3) . Interestingly, a proportion ( -10%) of the clonogenic progenitors was also found in the DRIOW or Rh-123d"" subpopulations of CD34+ CML blood cells. Although none of these were specifically genotyped, it is unlikely that significant numbers in either of these latter phenotypically defined "normal" subgroups were residual normal progenitors because normal progenitors, even if present at normal levels, would have accounted for less than 10% of the progenitors in the DRlow (Table 3) or Rh-123du11 fractions (data not shown) of all patients studied.
When the sorted CML cells were assayed for LTC-IC, the majority (-75%) were also present amongst the CD34+DRh1@ cells (Fig 3B) . This is also in contrast to normal LTC-IC, the majority of which in either blood ( -100%) or BM ( -55%) express little or no HLA-DR.I6J3
Thus, isolation of CD34+DRh1gh populations of cells from the PB of CML patients (either DR+ or DR++) yields a highly enriched LTC-IC population ( Table 2) . As noted for the circulating clonogenic cells in the same CML blood samples, a proportion of the LTC-IC (in this case, -30%) was also found in the CD34+DR1OW fraction. Because of the marked elevation in total LTC-IC numbers in these samples, the number of CD34+DRloW LTC-IC was also consis- tently greatly (> 5 0 0~) in excess of values for CD34+DR10w LTC-IC in the normal circulation (Table 3) . Similarly, most of the LTC-IC in the CML blood samples were Rh-123hr1&t (Fig 4B) , in contrast to the LTC-IC in either the blood or marrow of normal individual^.^^^^^ However, on average, approximately 20% of the circulating LTC-IC in patients with CML were found to have a Rh-123du11 phenotype, of which less than 1% would have been anticipated to be residual normal LTC-IC even if these were still present at normal levels (data not shown).
It can be seen from Table 1 that the initial frequencies of the clonogenic cells and LTC-IC in the CML blood samples studied, although elevated, were quite variable both on a
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volume and on a per nucleated cell basis. Variability was also encountered after these progenitors were separated into various subpopulations, as shown in Table 2 , for light density, CD34+, DR' OW or DRhigh cells. However, on average, the purity of circulating CML LTC-IC in the CD34+DR10W and CD34+DR+ fractions was approximately 10% (Table 2 ). This is approximately fivefold to sixfold higher than the purest populations of normal LTC-IC (1% to 2%) thus far isolated from normal blood or marrow samples.23,25,26,28 Corresponding values for the frequency of clonogenic cells in the CD34+DR1OW and CD34+DR+ fractions were 10% and 20% ( LTC-IC function was assessed in terms of the clonogenic cell content of LTC evaluated aftcr 4 and 8 wecks (rather than aftcr 5 weeks. as in the studies described above), because previous experiments had shown differences in the 4-HC sensitivity of normal LTC-IC measured by these two diffcrcnt endpoints.23. 31 Results for light-density CML blood cells exposed to I 0 0 pg/mL of 4-HC under standard transplant exposure conditions (ic, 2 x IO7 cclls/mL with 7% rcd blood cells for 30 minutes at 3PC) arc shown in Fig 5, together with previous data for normal progenitors tested using the same procedures and
Circulating CML clonogcnic cells and clonogcnic cells in normal marrow wcrc similarly reduced (to 10% of initial numbers) by this treatment. LTC-IC in the same CML blood samples appeared only slightly more resistant and wcrc significantly more scnsitivc (P < .OI) than normal LTC-IC from any source. §Calculated by multiplying the percentages of cells retrieved in the fraction indicated by the corresponding calculated enrichment in each individual experiment, and then deriving the mean f SEM of these values for the experiments performed, assuming 100% recovery after centrifugation on FH.
IlRefers to the light density (presort) population. TDefined in Fig 2D. Differentiative potential of CML LTC-IC. Previous studies have shown that the relative numbers of different types of clonogenic progenitors present in 5-week-old LTC provides a consistent average overall measure of the differentiative behavior of LTC-IC assayed under standard LTC conditions.16 To assess whether this parameter is altered in the LTC-IC present in CML blood, the ratio of BFU-E, CFU-GM, and CFU-GEMM numbers before and after LTC of light-density CML blood cells was assessed. As shown in Table 4 , after 5 weeks in LTC the proportion of progenitors identified as CFU-GM increased, as documented previously for LTC-IC in the blood and marrow of normal individuals,l6s" and this remained constant for an additional 3 weeks (data not shown).
DISCUSSION
This report describes a number of features of two functionally distinguished classes of primitive hematopoietic cells (clonogenic cells and LTC-IC) found in the blood of patients with CML. Both of these progenitor types are defined by quantitative assays that measure developmental potential using standardized culture conditions and specific progeny output endpoints, thus allowing comparison with Table 3 . Concentration of Various Subpopulations in CML Blood (n = 4) and Estimates of Potentially Normal (Phl-negative)
Components Assuming These Cells Were Present at the Same Concentration as in Normal Blood
Clonogenic Cells/mL
Mean * SEM similarly dcfincd normal cclls. Because normal (Phlncgativc) LTC-IC pcrsist in thc marrow of many CML patients (and to a much lcsscr cxtcnt, normal clonogcnic c~l l s ) . " '~"~~~ a sourcc of cells that would bc reproducibly, significantly, and prcfcrcntially enriched for ncoplastic progcnitors was uscd to avoid the nccd for laborious gcnotyping studies. CML patients with high WBC counts typically show markcd clcvations of both of thcsc progcnitor Thus, normal cclls, cvcn if prcscnt in such samplcs at normal Icvcls, would havc rcmaincd wcll bclow thc limit of detectability in any of thc separation cxpcrimcnts pcrformcd (as illustrated by thc calculations shown in Table 3 ). Prcvious studics aimcd spccifically at addrcssing this qucstion havc failcd to show cvidcncc of clcvatcd numbcrs of circulating normal progcnitors in patients with CML cvcn whcrc thcsc could havc bccn dctcctcd.32.u In addition, morc than 97% of LTC-IC from CML patients with high WBC counts and markedly clcvatcd LTC-IC concentrations havc rcccntly also bccn shown to exhibit abnormal functional propertics (ic, sclfmaintcnancc) in LTC, consistent with a leukemic origin."' Our rcsults dcscribcd hcrc show that the majority of both thc clonogcnic cclls and the LTC-IC in thc circulation of CML paticnts with high WBC counts arc phcnotypically similar to onc another with rcspcct to sizc (FSC). cxprcssion of CD34 and HLA-DR, uptakc of Rh-123, and sensitivity to 4-HC. In both cascs, thc prcdominant phcnotype was that cxpcctcd of prolifcrating or activatcd cclls (ic. high FSC, high expression of HLA-DR, high Rh-123 uptakc. and rclativc scnsitivity to 4-HC). On thc other hand, subtlc diffcrcnccs bctwccn circulating clonogcnic cclls (morc activated) and LTC-IC (Icss activatcd) in CML paticnts wcrc also consistcntly notcd. This prcdominant, "abnormal" phcnotypc is csscntially thc oppositc of that prcviously shown for thc majority of clonogcnic cclls and LTC-IC in thc circulation of normal adults, also sharcd by thc majority of LTC-IC in normal marrow (ic, low FSC, low expression of HLA-DR. low Rh-123 uptakc, and rclativc inscnsitivity to 4-HC). Thcsc findings thus confirm and cxtcnd prcvious cvidcncc that most of the clonogcnic cclls in CML blood arc CD34+HLA-DR+,35 and arc in agrccmcnt with thc rcportcd diffcrcncc in sizc and HLA-DR phcnotypc of normal and neoplastic LTC-IC that cocxist in CML marrow.* Such obscrvations arc consistcnt with thc likclihood that many Phl-positive LTC-IC, likc thcir clonogcnic progcny, will bc found to bc activcly prolifcrating cells rcgardlcss of thcir location in thc CML patient (in blood or marrow).n Dircct mcasurcmcnts of thc cycling status of LTC-IC arc not yct availablc, but should allow this prcdiction to bc formally tested.
It is of intcrcst that a substantial proportion (10% to 30%) of thc circulating progcnitors in thc blood of thc CML paticnts analyzed in this study showcd fcaturcs charactcristic of thcir countcrparts in normal individuals. As notcd abovc, it sccms vcry unlikcly that thcsc rcprcscntcd cocxisting normal clcmcnts, bccausc thc numbcrs involvcd would havc rcquircd thc lattcr to havc bccn greatly incrcascd in the circulation, a possibility not supportcd by cxisting data.33.M.37 Accordingly, onc might anticipate thc turnover of all classcs of primitive ncoplastic progcnitors in CML patients to bc incrcascd (ic, LTC-IC as wcll as clonogcnic cclls), although not maximally so, with grcatcr numbcrs of quicsccnt cclls occurring among thc Phi-positive LTC-IC population than among thcir clonogcnic progcny. In this regard, it is of intercst that primitivc lcukcmic progenitors from patients with CML havc been found to bc similarly rcsponsivc to thc cytostatic, but rcvcrsiblc, cffccts cxcrtcd by transforming growth factor+ (TGF-f3) on primitivc normal hcmatopoictic cclls in vitro.3x40 Altcrnativcly, it is possible that thc phcnotypic markcrs cxamincd may not By limiting dilution analysis, we previously showed that the total number of clonogenic cells produced on average by LTC-IC in normal blood or BM, or in CML blood is the same after 5 weeks in LTC, although in the same cultures the maintenance of normal LTC-IC is much better." Another functional endpoint of LTC-IC behavior in vitro examined here is provided by analysis of the relative numbers of the different types of clonogenic progeny they produce when maintained under LTC conditions. The present studies show that the ratio of erythroid-restricted, granulocyte-macrophage-restricted, and multilineage clonogenic cells generated by LTC-IC in the blood of CML patients with high WBC counts is indistinguishable from that previously documented for normal LTC-IC from all sources thus far a n a l y~e d .~~,~~ These findings reinforce the concept that the LTC-IC assay detects a functionally homogeneous population of primitive hematopoietic cells and that the processes underlying commitment to specific lineages are not substantially affected by the presence of the BCR-ABL gene.
In summary, we have shown that a majority of the most primitive neoplastic progenitors that are currently detectable in the circulation of patients with CML differ from their counterparts in normal individuals with respect to a number of functionally related properties. These differences are suggestive of a deregulation in the control of cell proliferation in CML at the level of the cells initially responsible for maintenance and expansion of the Phlpositive clone without alteration of their commitment to, or early differentiation down, each of the hematopoietic lineages. These findings may provide a potentially useful theoretical framework for future analysis of the mechanism of BCR-ABL-induced multilineage disease. On the other hand, from a practical viewpoint, the demonstration that, on average, as many as 30% of the circulating LTC-IC in CML patients were phenotypically indistinguishable from normal LTC-IC by the parameters studied (FSC, expression of HLA-DR, and uptake of Rh-123) does not auger well for the use of these properties to selectively isolate primitive normal stem cells from CML marrow harvests for autologous transplantation, particularly because significant contamination of such autografts with PB cells cannot be avoided. Further investigation of the basis of the phenotypic heterogeneity characteristic of primitive circulating cells in patients with CML will clearly be of interest. The procedures described here, which allow populations of these cells to be readily obtained at 10% to 20% purity and in high yield, should provide a useful starting point for such studies.
